NewAmsterdam Pharma N.V. (NAMS)
| Bid | 16.44 |
| Market Cap | 2.2B |
| Revenue (ttm) | 45.31M |
| Net Income (ttm) | -232.13M |
| EPS (ttm) | -2.56 |
| PE Ratio (ttm) | -7.81 |
| Forward PE | -10.99 |
| Analyst | Buy |
| Ask | 20.25 |
| Volume | 615,169 |
| Avg. Volume (20D) | 970,931 |
| Open | 19.37 |
| Previous Close | 19.13 |
| Day's Range | 18.70 - 20.10 |
| 52-Week Range | 14.06 - 27.29 |
| Beta | -0.00 |
About NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...
Analyst Forecast
According to 7 analyst ratings, the average rating for NAMS stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 110.11% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibNew Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to fi...
2 months ago · seekingalpha.com
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol RevolutionNewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures...